Neuromuscular Disorders
Viral and retroviral myositis
Jun. 16, 2026
Worddefinition
At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas.
Anti-IgLON5 disease …
- Updated 02.04.2026
- Released 09.16.2019
- Expires For CME 02.04.2029
Anti-IgLON5 disease
Introduction
Overview
Anti-IgLON5 disease is a neurologic disorder associated with antibodies in serum and CSF against IgLON5, a neuronal surface protein of unknown function. The disease is characterized by a distinctive sleep disorder associated with symptoms of bulbar dysfunction, gait instability, movement disorders (chorea and craniofacial dyskinesias) and other neurologic symptoms (cognitive impairment, oculomotor abnormalities, and neuromuscular manifestations). Anti-IgLON5 disease is associated with specific HLA haplotypes, but neuropathological examinations demonstrate neuronal loss in the hypothalamus and brainstem, accompanied in some patients by hyperphosphorylated tau aggregates that appear to be a secondary process that emerges with disease progression. Although the pathogenesis of anti-IgLON5 disease is not fully understood, current evidence suggests that autoimmune mechanisms may initiate a subsequent neurodegenerative process.
Key points
|
• Patients with anti-IgLON5 disease usually present a distinctive sleep disorder characterized by a NREM and REM parasomnia associated with stridor and obstructive sleep apnea. | |
|
• Neurologic symptoms beyond sleep are often the presenting symptom leading to medical consultation and may overshadow the sleep disorder. | |
|
• In addition to sleep problems, symptoms of bulbar dysfunction, gait abnormalities, and other movement disorders, including chorea and craniofacial dyskinesias, are frequent and prominent at disease presentation. | |
|
• Five major clinical phenotypes have been identified based on the predominant manifestations: (1) the sleep disorder, (2) a bulbar syndrome, (3) movement disorders, (4) cognitive impairment, and (5) neuromuscular manifestations. |
Historical note and terminology
Anti-IgLON5 disease was described in 2014 in eight patients presenting a neurologic syndrome with a prominent sleep disorder and antibodies directed to a neuronal surface protein named IgLON5 (27). Neuropathology in two patients showed neuronal loss and deposits of hyperphosphorylated tau protein in the brainstem tegmentum and hypothalamus. Since then, a substantial number (> 300) of cases have been reported (10; 18) and IgLON5 antibodies appear to be the third most frequent neuronal antibody against surface antigens, after NMDAR and LGI1 antibodies (02). The spectrum of neurologic symptoms and presentations is expanding (16), and cases without an underlying tauopathy have been reported (06; 08). The underlying pathophysiology of anti-IgLON5 disease is still unclear, but the current evidence supports a primary autoimmune pathogenesis that could lead to neurodegeneration with neuronal loss and associated tau deposits.
Clinical manifestations
Presentation and course
Anti-IgLON5 disease affects both genders similarly and usually develops between the 50s and 70s. Onset of symptoms is usually slowly progressive, but a rapid presentation occurs in up to 25% of the patients. The four most frequent initial complaints are sleep-related problems, symptoms of bulbar dysfunction (mainly dysphagia), gait difficulties with disequilibrium or ataxia, and movement disorders (eg, chorea and facial or abdominal dyskinesias). Other presenting symptoms include cognitive problems, and less frequently, oculomotor abnormalities (eg, diplopia) and neuromuscular manifestations (eg, fasciculations and weakness) (12; 10; 19; 18).
Sleep problems are present in more than 90% of the patients and can be the reason to seek medical attention (27; 12). Bed partners often report that patients, while asleep, present frequent episodes of vocalizations (eg, mumbling, whispering, groaning, moaning, and, less often, talking), movements (eg, jerks or limb flailing), and purposeful-looking gestures (eg, mimicking a daily life activity such as eating or manipulating an imaginary object). Bed partners also witness sleep apnea episodes and often report a “loud” respiratory noise during sleep usually referred to as an intense “snoring.” Patients are unaware of these sleep problems and may complain of insomnia with poor quality and nonrestorative sleep with mild to severe excessive daytime sleepiness. Video-polysomnographic studies show that sleep-related vocalizations and movements are related to a complex parasomnia involving both NREM and REM sleep. Obstructive sleep apnea is also frequent and is usually associated with stridor that accounts for the “loud” respiratory noise or “snoring” reported by bed partners (12; 14).
Despite the high frequency of sleep disturbances in about 60% to 70% of patients, other neurologic symptoms, such as gait difficulties, movement disorders (eg, chorea, craniofacial dyskinesias), dysphagia, or cognitive impairment, are the presenting and most disabling symptoms leading to medical consultation. In these patients, the sleep disorder can be overlooked because patients and bed partners do not spontaneously report the sleep problems, and doctors do not ask about them. Recognition of sleep disturbances in patients presenting these other neurologic problems may help doctors to suspect anti-IgLON5 disease. It is important to mention, however, that in up to 20% of the patients, sleep symptoms can be absent at disease onset, but they may appear later during the course of the disease (12; 10; 19).
Symptoms of bulbar dysfunction occur in 75% to 90% of patients with IgLON5 antibodies and include dysphagia, dysarthria, laryngeal stridor, or episodes of respiratory failure (12; 19; 30). Dysarthria is usually mild and characterized by dysphonic or slurred speech. Most patients present with mild swallowing problems, but in 20% to 40% of them, dysphagia is severe, causes a marked weight loss (up to 10-30 Kg), and requires the placement of a feeding tube or percutaneous endoscopic gastrostomy (31). In some patients, a feeding tube or percutaneous endoscopic gastrostomy can be required. Laryngoscopy demonstrates mild to moderate unilateral or bilateral vocal cord palsy in 60% of the patients. Although stridor during sleep is frequent, stridor during wakefulness is less common. Isolated or recurrent episodes of acute respiratory failure secondary to central hypoventilation or obstruction with laryngeal spasms and glottic narrowing can occur in about 40% of the patients, requiring ICU admission and ventilatory support, and even permanent tracheotomy (12; 10).
Gait and movements disorders are also present in 85% to 90% of patients with anti-IgLON5 disease (10). Gait and balance problems occur in 70% to 75% of the patients, and in over half of them, gait impairment is severe, with frequent falls or inability to walk. The disturbance of gait and balance in anti-IgLON5 disease is heterogeneous and complex. The three most common causes of gait impairment are: (1) disequilibrium with a broad-based gait, postural instability, and altered postural reflexes; (2) ataxic gait without postural instability (limb dysmetria and other cerebellar signs, however, are infrequent); and (3) combination of both. Less frequently, gait in IgLON5 patients is altered because of slow parkinsonian gait, freezing, or choreic movements (04; 12; 10; 19).
Besides gait problems, other movement disorders are also frequent. Chorea, affecting the limbs but also the trunk and face, is present in 30% of the patients (29; 12; 10). Craniofacial dyskinesias, manifesting as dystonia (eg, blepharospasm or orolingual or cervical dystonia), myorhythmia, myokymia, or isolated orolingual dyskinetic movements also occur in one third of the cases (10). In this sense, gait disturbances (disequilibrium or ataxic gait) associated with craniofacial dyskinesias or generalized chorea is a common combination and is observed in 40% of patients with anti-IgLON5 disease (10). Parkinsonism has been reported in 20% to 30% of IgLON5 patients, although it is usually mild, of the rigid-akinetic type, and does not improve with levodopa. Abnormal body postures (eg, antecollis, lateral bending of the trunk) can occur in 20% of the patients. Less frequent movements disorders in anti-IgLON5 disease are akathisia, distal limb myoclonus, hand tremor, limb dystonia, or myoclonic movements in the trunk or abdomen. Limb rigidity and spams like those of stiff-person syndrome have also been reported in a few patients (31; 23; 10).
Other frequent symptoms at presentation or during the disease course are cognitive problems, oculomotor abnormalities, dysautonomia, and neuromuscular symptoms. Cognitive complaints are reported in 40% to 60% of the patients, and about 50% of them fulfill criteria of dementia with impairment of attention, episodic memory, and executive function (29; 12; 11). In some patients, cognitive problems may be accompanied by neuropsychiatric symptoms, such as delusions and hallucinations (18). Oculomotor abnormalities are present in one third of the patients, some of them complaining of diplopia. Neurologic examination may show supranuclear gaze palsy with predominant upward or horizontal gaze limitation (downward gaze palsy is rare). Nystagmus and abnormalities in saccadic or pursuit eye movements have also been reported (05; 12; 19). Eyelid ptosis is a subtle sign that can be seen in 21% of the patients (10). Dysautonomia (45% to 65% of the patients) is usually mild. Urinary dysfunction with increased frequency, urgency, or incontinence is the most frequent dysautonomic symptom. Episodes of intense perspiration are sometimes reported. Less frequently, some patients complain of anhidrosis or heat-cold intolerance. Orthostatic hypotension is infrequent. Autonomic cardiac dysfunction with ventricular tachycardia or severe bradycardia is infrequently reported. A few cases can present neuromuscular symptoms, including fasciculations. Less frequent symptoms are cramps, limb weakness and wasting (12; 10; 19; 30). Bilateral optic neuropathy with papilledema has also been reported (07).
All these symptoms can appear in different combinations, severity, and timelines—at disease onset or throughout the evolution of the disease—leading to different clinical presentations, including (1) a sleep disorder with abnormal movements and behaviors and sleep-disordered breathing; (2) a bulbar syndrome, including dysphagia, dysarthria, and respiratory failure; (3) movement disorders with diverse presentations (i) a syndrome resembling progressive supranuclear palsy (progressive supranuclear palsy–like subtype), with gait instability and oculomotor abnormalities; (ii) gait ataxia, (iii) generalized chorea or craniofacial or abdominal dyskinesias; and (iv) a syndrome of limb stiffness and spasms resembling a stiff-person syndrome); (4) cognitive impairment with dementia, in some instances associated with chorea (leading to a syndrome mimicking Huntington disease); and (5) a neuromuscular syndrome with fasciculations and muscular wasting, often with bulbar symptoms, resembling a lower motor neuron disease (12; 10; 19; 31; 30). The disease can have a subacute presentation in some patients, and an encephalitic-like presentation has been reported in a few atypical cases (22; 24).
Prognosis and complications
The prognosis is poor, and depending on the series, mortality occurs in 19% to 40% of the patients 2 to 5 years after disease onset (19; 18; 17; 09). Up to half of the patients die suddenly, either during wakefulness or sleep. Respiratory failure secondary to central hypoventilation or obstruction with laryngeal spasms, and aspiration pneumonia related to swallowing difficulties, are frequent complications and additional important causes of death (12; 20). Emerging evidence indicates that bulbar involvement (manifesting as dysphagia, vocal cord palsy, and respiratory compromise) and elevated serum neurofilament light chain levels are predictors of unfavorable prognosis and increased mortality (18; 09).
Anti-IgLON5 disease appears to follow a chronic progressive course in most patients, with subacute relapses occurring in up to 51% of the patients in the subsequent 1 to 3 years after diagnosis (18). The natural history of anti-IgLON5 disease, however, is still not well-known, and progression is heterogeneous, with variable outcomes. The IGLON5 Composite Score (ICS) has been developed as a scale to assess symptoms severity in anti-IGLON5 disease. The ICS evaluates 17 symptoms grouped into five major clinical domains that cover most symptoms of the disease (bulbar, sleep, movement disorders, cognition, and others) and is useful for monitoring immunotherapy response and disease progression (13).
Clinical vignette
A 76-year-old female consulted with the emergency department because of a 3-week history of gait difficulties with falls. Mild speech difficulties and dysphagia were also present. Neurologic examination showed gait initiation failure with short-stepped and slightly wide-based gait and severe imbalance with abolished postural reflexes. Additional findings included saccadic intrusions on pursuit eye movements and mild dysarthria. Two days after in-hospital admission, she developed sudden respiratory failure with central hypoventilation that required intubation. Only when asked about her sleep, her husband reported a previous 4-month history of loud respiratory noise with frequent vocalizations and jerky movements during sleep. High-dose intravenous steroids improved respiratory function, and the patient was weaned and transferred to the neurology ward. Video-polysomnography recorded a NREM parasomnia with frequent vocalizations, movements, and complex behaviors; REM sleep without atonia; and periods of normal NREM sleep with sleep spindles, K complexes, and delta slowing with stridor and obstructive sleep apnea (apnea-hypopnea index: 23). A laryngoscopy confirmed bilateral vocal cord paresis. Routine blood and CSF analysis, brain MRI, EMG, and thoracic CT were normal. Intravenous cyclophosphamide resulted in mild improvement in balance and gait. The patient was discharged to a nursing home, but she died suddenly while asleep 6 months later.
Biological basis
Etiology and pathogenesis
The etiology of anti-IgLON5 disease is unknown, but the current evidence supports a primary autoimmune pathogenesis. Initial neuropathological studies in patients with anti-IgLON5 disease revealed features of neurodegeneration with neuronal loss and deposits of hyperphosphorylated tau protein, predominantly in the tegmentum of the brainstem and hypothalamus, defining a novel neuronal tauopathy (27). These findings, in addition to the insidious onset and slow progression of symptoms and lack of response to immunotherapy in many patients, suggested an underlying neurodegenerative process.
However, neuronal loss with tau deposits is not universal and is absent in some patients (06; 08). Autopsy studies have delineated a continuum of anti‑IgLON5–related neuropathology ranging from minimal or non‑tau pathology (stage 1) to a severe mixed 3R/4R neuronal tauopathy predominantly affecting the brainstem (stage 3). In patients with long‑standing disease, hyperphosphorylated tau pathology mainly involves the hypothalamus and brainstem tegmentum, whereas early fatalities typically show no tau deposition. However, phosphorylation at serine 422 of tau proteins has been identified as one of the first alterations at stage 1, with simultaneous anti-IgLON5 IgG4 deposits on the neuronal surface as observed by double immunolabeling (25). Moreover, perivascular and parenchymal inflammatory infiltrates composed of B and T lymphocytes, together with neuronal MHC class I upregulation and microglial activation, have also been reported. These findings further support the notion that tau aggregation is a secondary process likely driven by immune‑mediated mechanisms (15).
An additional observation supporting a crucial role for autoimmunity in the disease pathogenesis is the strong association with specific HLA haplotypes. The HLA DRB1*10:01 and DQB1*05:01 alleles are present in 55% to 60% of patients with anti-IgLON5 disease. The allele DRB1*10:01 is very uncommon in the general population, with a frequency of about 1% (the association with the DQB1*05:01 allele can be explained because of its genetic linkage with DRB1*10:01) (11; 10). More recent evidence, however, indicates a possible stronger association with HLA-DQ compared to HLA-DR, as the alleles HLA-DQA1*01:05–DQB1*05:01, HLA-DQA1*01:01–DQB1*05:01, and HLA-DQA1*01:04–DQB1*05:03 have been identified in approximately 85% of patients with anti-IgLON5 disease and a deamidated peptide derived from the Ig2 domain of IgLON5 has been shown to activate T cells through the HLA-DQA1*01:05–DQB1*05:01 haplotype, supporting that an HLA-DQ–mediated T-cell response to IgLON5 may represent a potential pathogenic trigger of the disease (33).
In addition, IgLON5 antibodies cause an irreversible internalization of surface IgLON5 protein in cultures of hippocampal neurons that is associated with a cytoskeletal disruption with dystrophic neurites and axonal swelling (28; 21), supporting the hypothesis that the antibody could interfere with the interaction between IgLON5 protein and the internal cytoskeletal network leading to neuronal dysfunction and, as a secondary event, neurodegeneration with tau accumulation (26). At present, the function of IgLON5 is still unknown, and a better understanding of the physiology of this cell-adhesion protein is essential to elucidate the pathogenesis of the disease (16). Finally, despite strong evidence pointing to an autoimmune origin of the disease, at present, the few published studies attempting the passive transfer of the antibodies of the patients to rodent animal models have failed to reproduce the typical clinical symptoms of the disease or the described in vitro effects of the antibodies, which would be definitive proof of the pathogenic role of the antibodies (01; 16).
Epidemiology
Anti-IgLON5 disease is a rare disorder but is also underdiagnosed. Its incidence and prevalence are unknown. When compared to other autoimmune encephalitis or CNS disorders associated with neuronal antibodies against surface antigens, anti-IgLON5 disease is the third most frequent (8.5%) after NMDAR and LGI1 encephalitis, which represent 30% and 32% of the cases, respectively (02).
Prevention
At present, no preventative strategies are known.
Differential diagnosis
Confusing conditions
The differential diagnosis of anti-IgLON5 disease includes several neurodegenerative and autoimmune diseases. Patients can be misdiagnosed as progressive supranuclear palsy if gait instability and oculomotor abnormalities are prominent, although typical downward gaze palsy is rare, and parkinsonism is usually not prominent in IgLON5 patients (05; 12). The combination of gait ataxia, stridor, and sleep problems may resemble multiple system atrophy, but dysautonomia, if present, is usually mild, and severe orthostatic hypotension is absent in IgLON5 patients (10). Huntington disease can be suspected, particularly when cognitive impairment is associated with chorea (29). If dementia is the main problem, some patients can be misdiagnosed as Alzheimer disease or dementia with Lewy bodies (03). Some patients can present orolingual myorhythmia, and their clinical picture may resemble Whipple disease, but myorhythmia does not involve the eyes in IgLON5 patients (19; 23). Stiff-person syndrome is also another differential diagnosis in patients presenting with stiffness and cramps (19; 31). Myasthenia gravis can also be considered in patients with symptoms of bulbar dysfunction and respiratory failure. In addition, if fasciculations are present, a motor neuron disease can be misdiagnosed (30). In patients in whom these disorders are suspected but diagnostic criteria are not fulfilled, or for whom the confirmatory laboratory tests are negative, anti-IgLON5 disease has to be suspected, particularly if significant sleep problems are present. The sleep disorder in anti-IgLON5 disease can be misinterpreted as isolated obstructive sleep apnea syndrome, REM sleep behavior disorder, status dissociatus, or oneiric stupor and agrypnia excitata (14).
Associated or underlying disorders
Anti-IgLON5 disease is not associated with tumors, cancers, or other autoimmune disorders. In one study, the frequency of present or past history of cancer was 15%, and for autoimmune diseases was 11%, frequencies similar to that expected in the general population (18).
Diagnostic workup
The presence of antibodies against IgLON5 in serum and CSF are the diagnostic hallmark of the disease. CSF analysis is frequently normal, but mild lymphocytic pleocytosis occurs in less than one third of the patients, whereas mild protein increase is present in about 50% of them. Oligoclonal bands in CSF are usually absent. Brain MRI in most patients is normal or shows nonspecific findings. In a few patients, marked brainstem and cerebellar atrophy, or hippocampal, hypothalamic, and frontotemporal hyperintensities have been reported (32). Volumetric MRI studies in anti‑IgLON5 disease revealed a specific pattern of regional brain atrophy predominantly affecting the hypothalamus, brainstem, and basal ganglia, corresponding to the regions with the maximal neuropathological involvement.
EEG is normal in most cases. EMG can reveal subclinical evidence of fasciculation in up to 50% of the patients (18). Laryngoscopy may show unilateral or bilateral vocal cord abductor paresis (12; 19; 22).
In most patients, video polysomnography shows the characteristic sleep disorder of anti-IgLON5 disease. The main polysomnographic features of this sleep disorder include the following.
(1) An NREM parasomnia with abnormal sleep initiation occurring as undifferentiated NREM sleep (characterized by the presence of diffuse irregular theta activity without vertex waves, K complexes, sleep spindles, or delta slowing) or poorly structured N2 NREM sleep (with sparse but well-defined sleep spindles and K complexes), both associated with motor activation with frequent vocalizations (eg, murmuring, whispering, groaning, or talking) and simple or purposeful-looking movements (eg, resembling an activity of daily life, such as eating, drinking, manipulating, or picking up objects)
(2) Periods of normal NREM sleep that typically appear following undifferentiated NREM sleep and poorly structured N2 NREM sleep, with frequent sleep spindles and delta slowing without motor activation
(3) REM sleep behavior disorder, with loss of muscle atonia and frequent limb and body jerks
(4) Frequent obstructive sleep apnea with stridor, more prominent during periods of normal NREM sleep. Some of these features can be absent in some patients in whom NREM sleep is completely normal, muscle atonia in REM sleep is preserved, or stridor is absent (05; 12; 14).
HLA typing shows that 55% to 60% of the patients are DRB1*10:01 and DQB1*05:01 positive. There are a few atypical patients with antibodies against IgLON5 positive in serum but negative in CSF. These patients tended to present the progressive supranuclear palsy–like phenotype and have other atypical features, such as absence of the characteristic sleep disorder and HLA-DRB1*10:01 negativity (12).
Management
There is no robust evidence (eg, clinical trials) to provide adequate recommendations for standardized treatment protocol in anti-IgLON5 disease. There are multiple reports of patients with anti‑IgLON5 disease improving with immunotherapy, including steroids, intravenous immunoglobulins, cyclophosphamide, rituximab, or plasma exchange (04; 19; 30). Up to 41% of patients may show a clinical response to immunotherapy (10; 18). In a retrospective study of 107 patients with anti‑IgLON5 disease, early immunotherapy within the first year after symptom onset was associated with lower long‑term disability and improved survival (17). In this study, a small subset of patients received early intravenous immunoglobulins and appeared to have a better outcome compared to other treatments, but this effect needs to be confirmed in future prospective studies.
Obstructive sleep apnea and stridor are eliminated with both continuous positive airway pressure and tracheotomy, which also improve excessive daytime sleepiness. The NREM and REM parasomnia did not improve with continuous positive airway pressure, clonazepam, or other treatments. Patients often require symptomatic management, including treatments for movement disorders, placement of a feeding tube or percutaneous endoscopic gastrostomy for severe dysphagia, and admission to the intensive care unit with ventilatory support. Permanent tracheotomy could be necessary and lifesaving in patients with recurrent episodes of acute respiratory failure related to laryngospasms or severe vocal cord palsy (12).
Outcomes
Rates of response to immunotherapy in anti-IgLON5 disease ranged from 13% to 41% in different retrospective case series (10; 18). This response, however, is usually partial, and not all symptoms improve. The benefit of immunotherapy is also frequently transient, with a subsequent worsening of the symptoms weeks or months later. In some series, a possible factor associated with favorable response to immunotherapy is early treatment in the course of the disease (19; 18; 17).
Media
References
- 01
- Alvente S, Matteoli G, Molina-Porcel L, et al. Pilot study of the effects of chronic intracerebroventricular infusion of human anti-IgLON5 disease antibodies in mice. Cells 2022;11(6):1024. PMID 35326477
- 02
- Arino H, Ruiz García R, Rioseras B, et al. Frequency and referral patterns of neural antibody studies during the COVID-19 pandemic: experience from an autoimmune neurology center. Neurol Neuroimmunol Neuroinflamm 2023;10(4):e200129. PMID 37311644
- 03
- Bastiaansen AEM, van Steenhoven RW, Te Vaarwerk ES, et al. Antibodies associated with autoimmune encephalitis in patients with presumed neurodegenerative dementia. Neurol Neuroimmunol Neuroinflamm 2023;10(5):e200137. PMID 37311646
- 04
- Bonello M, Jacob A, Ellul MA, et al. IgLON5 disease responsive to immunotherapy. Neurol Neuroimmunol Neuroinflamm 2017;4(5):e383. PMID 28840176
- 05
- Brüggemann N, Wandinger KP, Gaig C, et al. Dystonia, lower limb stiffness, and upward gaze palsy in a patient with IgLON5 antibodies. Mov Disord 2016;31(5):762-4. PMID 27030137
- 06
- Cagnin A, Mariotto S, Fiorini M, et al. Microglial and neuronal TDP-43 pathology in anti-IgLON5-related tauopathy. J Alzheimers Dis 2017;59(1):13-20. PMID 28550263
- 07
- Demortiere S, Joubert B, Benaiteau M, et al. Anti-IgLON5 disease with inaugural bilateral neuropapillitis. Neurology 2024;102(8):e209284. PMID 38527243
- 08
- Erro ME, Sabater L, Martínez L, et al. Anti-IGLON5 disease: a new case without neuropathologic evidence of brainstem tauopathy. Neurol Neuroimmunol Neuroinflamm 2019;7(2):e651. PMID 31826985
- 09
- Farina A, Villagrán-García M, Abichou-Klich A, et al. Serum neurofilament light chain correlates with clinical severity and predicts mortality in anti-IgLON5 disease. Neurol Neuroimmunol Neuroinflamm 2025;12(6):e200498. PMID 41061184
- 10
- Gaig C, Compta Y, Heidbreder A, et al. Frequency and characterization of movement disorders in anti-IgLON5 disease. Neurology 2021;97(14):e1367-81.** PMID 34380749
- 11
- Gaig C, Ercilla G, Daura X, et al. HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. Neurol Neuroimmunol Neuroinflamm 2019b;6(6). PMID 31454761
- 12
- Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology 2017;88(18):1736-43. PMID 28381508
- 13
- Gaig C, Grüter T, Heidbreder A, et al. Development of a composite score for the clinical assessment of anti-IgLON5 disease. Neurology 2024;102(7):e208101. PMID 38457758
- 14
- Gaig C, Iranzo A, Cajochen C, et al. Characterization of the sleep disorder of anti-IgLON5 disease. Sleep 2019a;42(9):zsz133. PMID 31198936
- 15
- Gelpi E, Reinecke R, Gaig C, et al. Neuropathological spectrum of anti-IgLON5 disease and stages of brainstem tau pathology: updated neuropathological research criteria of the disease-related tauopathy. Acta Neuropathol 2024;148(1):53.** PMID 39400557
- 16
- Graus F, Sabater L, Gaig C, et al. Anti-IgLON5 disease 10 years later: what we know and what we do not know. Neurol Neuroimmunol Neuroinflamm 2025;12:e200353.** PMID 39705634
- 17
- Gruter T, Gaig C, Crijnen YS, et al. Early treatment with intravenous immunoglobulins and outcomes of patients with anti-IgLON5 disease. JAMA Neurol 2025;82(10):1040-7. PMID 40758377
- 18
- Gruter T, Möllers FE, Tietz A, et al. Clinical, serological and genetic predictors of response to immunotherapy in anti-IgLON5 disease. Brain 2023;146(2):600-11.** PMID 35259208
- 19
- Honorat JA, Komorowski L, Josephs KA, et al. IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm 201718;4(5):e385.** PMID 28761904
- 20
- Howischer T, Gattermeyer-Kell L, Hirschbichler S, et al. Causes of death in anti-IgLON5 disease: a novel case report and systematic literature review. Brain Sci 2025;15(9):921. PMID 41008281
- 21
- Landa J, Gaig C, Plagumà J, et al. Effects of IgLON5 antibodies on neuronal cytoskeleton: a link between autoimmunity and neurodegeneration. Ann Neurol 2020;88(5):1023-7.** PMID 32740999
- 22
- Montagna M, Amir R, De Volder I, Lammens M, Huyskens J, Willekens B. IgLON5-associated encephalitis with atypical brain magnetic resonance imaging and cerebrospinal fluid changes. Front Neurol 2018;9:329. PMID 29867738
- 23
- Morales-Briceño H, Cruse B, Fois AF, et al. IgLON5-mediated neurodegeneration is a differential diagnosis of CNS Whipple disease. Neurology 2018;90(24):1113-5. PMID 29769372
- 24
- Ramanan VK, Crum BA, McKeon A. Subacute encephalitis with recovery in IgLON5 autoimmunity. Neurol Neuroimmunol Neuroinflamm 2018;5(5):e485. PMID 30175159
- 25
- Reinecke R, Nitsch S, Faber F, et al. Brainstem pathology in anti-IgLON5 disease: new insights into early events and tau progression. Brain 2026149(5):1704-17. PMID 41544664
- 26
- Ryding M, Gamre M, Nissen MS, et al. Neurodegeneration induced by anti-IgLON5 antibodies studied in induced pluripotent stem cell-derived human neurons. Cells 2021;10(4):837. PMID 33917676
- 27
- Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014;13(6):575-86.** PMID 24703753
- 28
- Sabater L, Planagumà J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation 2016;13(1):226.** PMID 27586161
- 29
- Simabukuro MM, Sabater L, Adoni T, et al. Sleep disorder, chorea, and dementia associated with IgLON5 antibodies. Neurol Neuroimmunol Neuroinflamm 2015;2(4):e136. PMID 26236762
- 30
- Werner J, Jelcic I, Schwarz EI, et al. Anti-IgLON5 disease: a new bulbar-onset motor neuron mimic syndrome. Neurol Neuroimmunol Neuroinflamm 2021;8(2):e962. PMID 33531378
- 31
- Wenninger S. Expanding the clinical spectrum of IgLON5-syndrome. J Neuromuscul Dis 2017;4(4):337-9. PMID 29103046
- 32
- Yogeshwar SM, Bartels F, Grüter T, et al. Brain atrophy patterns in anti-IgLON5 disease. Brain 2026;149(3):884-96. PMID 40650880
- 33
- Yogeshwar SM, Muñiz-Castrillo S, Sabater L, et al. HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease. Brain 2024;147(7):2579-92. PMID 38425314
Contributors
All contributors' financial relationships have been reviewed and mitigated to ensure that this and every other article is free from commercial bias.
Author
-
Carles Gaig MD PhD
Dr. Gaig of Hospital Clínic of Barcelona has no relevant financial relationships to disclose.
See Profile
Editor
-
Francesc Graus MD PhD
Dr. Graus, Emeritus Professor, Laboratory Clinical and Experimental Neuroimmunology, Institut D’Investigacions Biomédiques August Pi I Sunyer, Hospital Clinic, Spain, has no relevant financial relationships to disclose.
See Profile
Patient Profile
- Age range of presentation
-
- 45 to 65+ years
- Sex preponderance
-
- female = male
- Heredity
-
- none
- Population groups selectively affected
-
- none
- Occupation groups selectively affected
-
- none
ICD & OMIM codes
- ICD-10
-
- Other encephalitis, myelitis and encephalomyelitis: G04.8
This is an article preview.
Start a Free Account
to access the full version.
-
Nearly 3,000 illustrations, including video clips of neurologic disorders.
-
Every article is reviewed by our esteemed Editorial Board for accuracy and currency.
-
Full spectrum of neurology in 1,200 comprehensive articles.
-
Listen to MedLink on the go with Audio versions of each article.
Questions or Comment?
MedLink, LLC
3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122
Toll Free (U.S. + Canada): 800-452-2400
US Number: +1-619-640-4660
Support: service@medlink.com
Editor: editor@medlink.com
ISSN: 2831-9125
Also in This Category
-
-
Neuropharmacology & Neurotherapeutics
Upadacitinib
May. 14, 2026
-
General Child Neurology
Guillain-Barre syndrome in children
Apr. 24, 2026
-
Neuromuscular Disorders
Efgartigimod alfa-fcab
Apr. 23, 2026
-
Neuromuscular Disorders
Efgartigimod alfa and hyaluronidase-qvfc
Apr. 23, 2026
-
Neuropharmacology & Neurotherapeutics
Ofatumumab
Apr. 23, 2026
-
Neuroimmunology
Neuropathies associated with cryoglobulinemia
Mar. 29, 2026
-
Neuroimmunology
Rheumatoid arthritis: neurologic manifestations
Mar. 20, 2026